Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Genexine

    Client Virtual Booth

    GENEXINE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Genexine
    korearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    700 Daewangpangyo-ro, Korea Bio Park Bldg. B, Bundang-gu, Seongnam-si, Gyeonggi-do 13488
    Telephone
    Telephone
    +82 31 628 3200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.genexine.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/genexine-inc-
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
    Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

    https://www.businesswire.com/news/home/20231022313600/en

    BUSINESSWIRE
    23 Oct 2023
    Share Share
    Genexine's weekly growth hormone equal to Novo shot in phase 3
    Genexine's weekly growth hormone equal to Novo shot in phase 3

    https://www.fiercebiotech.com/biotech/genexines-weekly-growth-hormone-equal-novo-shot-phase-3-teeing-filing-china

    Nick Paul Taylor FIERCE BIOTECH
    31 Aug 2023
    Share Share
    Genexine Abstract on GX-188E and GX-I7 Therapy in HNSCC Is Released
    Genexine Abstract on GX-188E and GX-I7 Therapy in HNSCC Is Released

    https://www.businesswire.com/news/home/20230525005928/en

    BUSINESSWIRE
    26 May 2023
    Share Share
    Genexine says long-acting anaemia therapy succeeds against Roche, CSL's Mircera
    Genexine says long-acting anaemia therapy succeeds against Roche, CSL's Mircera

    https://www.businesswire.com/news/home/20230411005535/en/Genexine%E2%80%99s-Long-acting-Anemia-Treatment-GX-E4-Phase-3-Clinical-Trial-Interim-Result-Is-Presented-at-WCN2023-Confirmed-Non-inferiority-Compared-to-Mircera

    BUSINESSWIRE
    12 Apr 2023
    Share Share
    Genexine Receives Fast Track Designation from MFDS for DNA vaccine
    Genexine Receives Fast Track Designation from MFDS for DNA vaccine

    https://www.businesswire.com/news/home/20230120005433/en

    BUSINESSWIRE
    20 Jan 2023
    Share Share
    Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program
    Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program

    https://www.businesswire.com/news/home/20230108005070/en

    BUSINESSWIRE
    08 Jan 2023
    Share Share
    Genexine’s DNA Vaccine Shows Potential to Extend Survival in Cervical Cancer
    Genexine’s DNA Vaccine Shows Potential to Extend Survival in Cervical Cancer

    https://www.businesswire.com/news/home/20220907006295/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Genexine selected for Presentation of PII Study of GX-188E
    Genexine selected for Presentation of PII Study of GX-188E

    https://www.businesswire.com/news/home/20220824005804/en

    BUSINESSWIRE
    25 Aug 2022
    Share Share
    Patient with HNSCC dosed with triple combo therapy in PII of Genexine trial
    Patient with HNSCC dosed with triple combo therapy in PII of Genexine trial

    http://www.pharmafile.com/news/730030/patient-hnscc-dosed-triple-combination-therapy-phase-ii-genexine-clinical-trial

    PHARMAFILE
    17 Aug 2022
    Share Share
    Genexine Completes Enrollment in PIII Trial with GX-H9/TJ101
    Genexine Completes Enrollment in PIII Trial with GX-H9/TJ101

    https://www.biospace.com/article/releases/genexine-announces-completion-of-enrollment-in-phase-3-clinical-trial-with-its-proprietary-long-acting-growth-hormone-gx-h9-tj101-eftansomatropin-alfa-/

    BIOSPACE
    14 Jun 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search